Huntington's disease siRNA therapeutic - Argo Biopharma
Latest Information Update: 05 Mar 2024
At a glance
- Originator Argo Biopharma
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Huntington's disease
Highest Development Phases
- Preclinical Huntington's disease
Most Recent Events
- 21 Feb 2024 Huntington's Disease siRNA therapeutic - Argo Biopharma is available for licensing as of 21 Feb 2024. https://www.argobiopharma.com/partnering/index.html prior to February 2024 (Argo Biopharma pipeline, February 2024)
- 21 Feb 2024 Preclinical trials in Huntington's disease in China (Parenteral), prior to February 2024 (Argo Biopharma pipeline, February 2024)